The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
30-Oct-12
$834 million
Target:
Investments of AP Alternative Assets, L.P.
Acquiror:
Athene Holding Ltd.
Advised the Special Committee of the Conflicts Committee of the Board of Directors of Athene Holding Ltd. in connection with the purchase of non-cash investment assets of AP Alternative Assets L.P.
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
17-Nov-11
$1.5 billion
Target:
Northern Rock
Acquiror:
Virgin Money
Advised Virgin Money, a financial services provider, on the acquisition of Northern Rock, a UK retail mortgage and savings bank, from UK Financial Investments Ltd, which manages the UK Government’s investments in financial institutions
08-Jun-11
$1.7 billion
Target:
Citigroup (selected private equity assets)
Acquiror:
AXA Private Equity
Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
21-Mar-11
$NA
Target:
Close Brothers Cayman Limited
Acquiror:
Intertrust Group Holdings SA
Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA
11-Mar-11
$1.0 billion
Target:
Troika Dialog Group Limited
Acquiror:
Sberbank
Advised TD Advisors Limited, a major shareholder of Troika Dialog Group, Russia’s leading investment bank, on the sale of their stake as part of the acquisition of Troika Dialog Group by Sberbank, the largest commercial bank in Russia
01-Mar-11
$128 million
Target:
Tyndall Investments
Acquiror:
Nikko Asset Management
Advised Suncorp, on the sale of its investment management business, Tyndall Investments, in Australia and New Zealand to Nikko Asset Management, a leading Asian mutual funds management company
01-Mar-11
$122 million
Target:
Australian Unity Limited
Advised Australian Unity Limited, a leading healthcare, financial services and retirement living mutual organisation, on its A$120 million issue of five year unsecured notes listed on the Australian Stock Exchange
29-Dec-10
$1.8 billion
Target:
TOWER Australia Group Limited
Acquiror:
The Dai-ichi Life Insurance Company, Limited
Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
12-Nov-10
$NA
Target:
Money Controls (subsidiary of Coin Acceptors, Inc.)
Acquiror:
Crane Co.
Advised Coin Acceptors, Inc. (“CoinCo”), a privately-owned US-based manufacturer of payment solutions for the automated point-of-sale industry, on the sale of its UK-based Money Controls subsidiary to Crane Co., a diversified manufacturer of highly engineered industrial products
26-Oct-10
$175 million
Target:
Rural Bank
Acquiror:
Bendigo and Adelaide Bank
Advised Elders, a diversified agricultural company on the sale of its 40% stake in Rural Bank to Bendigo and Adelaide Bank, an Australian diversified financial services company
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
28-Jun-10
$1.3 billion
Target:
Guinness Peat Group plc
Advised GPG plc, a listed investment company, on potential restructuring alternatives
22-Apr-10
$1.9 billion
Target:
Bank of America Corporation
Acquiror:
AXA Private Equity
Advised AXA Private Equity, a leading European diversified private equity firm, on the acquisition of a portfolio of limited partnership interests in private equity funds from Bank of America
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
06-Jul-09
$2.0 billion
Target:
PARIS RE Holdings Ltd.
Acquiror:
PartnerRe Ltd.
Advised PartnerRe Ltd., a leading global reinsurer, providing multi-line reinsurance to insurance companies, on its acquisition of PARIS RE Holdings Ltd., a French-listed, Swiss-based diversified reinsurer
28-May-09
$107 million
Target:
Tristone Capital Global Inc.
Acquiror:
Macquarie Group
Advised Tristone Capital Global Inc., an independent advisory firm focused on the global energy sector, on its sale to Macquarie Group
18-May-09
$114 million
Target:
Close Brothers Corporate Finance Holdings Ltd.
Acquiror:
Daiwa Securities SMBC Europe Ltd.
Advised Close Brothers Group plc, an independent financial services group, on the sale of its corporate finance subsidiary to Daiwa Securities SMBC Europe Ltd.
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company